These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26622838)

  • 1. Synthesis and positron emission tomography evaluation of
    Fan W; Zhang Z; Zhu Z; Yang D; Chen X; Wang J; Chen F; Song X
    Oncol Lett; 2015 Oct; 10(4):2299-2302. PubMed ID: 26622838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
    Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
    Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.
    Chen Y; Foss CA; Byun Y; Nimmagadda S; Pullambhatla M; Fox JJ; Castanares M; Lupold SE; Babich JW; Mease RC; Pomper MG
    J Med Chem; 2008 Dec; 51(24):7933-43. PubMed ID: 19053825
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM
    Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
    Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties.
    Xia L; Liu Y; Cai P; Feng Y; Yuan H; Tang S; Wang YW; Liu N; Chen Y; Zhou Z
    Mol Imaging Biol; 2023 Aug; 25(4):765-775. PubMed ID: 36695967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models.
    Bouvet V; Wuest M; Jans HS; Janzen N; Genady AR; Valliant JF; Benard F; Wuest F
    EJNMMI Res; 2016 Dec; 6(1):40. PubMed ID: 27142881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a [Al
    Al-Momani E; Israel I; Samnick S
    Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Evaluation of
    Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation and first in human study of Al
    Ren Y; Liu C; Liu T; Duan X; Zhang Q; Liu J; Wang P; Guo Q; Yang X; Du P; Zhu H; Yang Z
    Front Oncol; 2022; 12():1030187. PubMed ID: 36338719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
    Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
    Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraindividual Comparison of
    Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
    J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiochemistry and Preclinical PET Imaging of
    Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
    Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.